Aug 6th, 9:30 AM - 12:00 PM

Expression of an alternate splice form of Bmi-1 in multiple myeloma

Adam Austin  
*University of Nevada Las Vegas*

Kristine Veys  
*University of Nevada Las Vegas*

Debbie Wong  
*University of Nevada Las Vegas*

James Tung  
*Nevada Cancer Institute, Division of Laboratory Medicine, Mentor*

Repository Citation
Austin, Adam; Veys, Kristine; Wong, Debbie; and Tung, James, "Expression of an alternate splice form of Bmi-1 in multiple myeloma" (2009). Undergraduate Research Opportunities Program (UROP). 3.  

This Event is brought to you for free and open access by the Undergraduate Research at Digital Scholarship@UNLV. It has been accepted for inclusion in Undergraduate Research Opportunities Program (UROP) by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.
Expression of an alternate splice form of Bmi-1 in multiple myeloma
The concept of “tumor stem cells” has garnered much attention in the last few years. Tumor stem cells are believed to exist among a heterogeneous group of cells that constitute a tumor. These tumor stem cells often express genes that are important for stem cell function, cell division, and maintenance of pluripotent state in stem cells. Stem cell or stem cell maintenance genes such as SALL4 and Bmi-1 are often seen in these cancer cells and contribute to self-renewing divisions and cancer cell survival. In particular, high expression of Bmi-1 (B lymphoma mouse Moloney leukemia virus insertion region), a member of the polycomb family of transcription factors, is often associated with poor prognosis in cancers.

Our laboratory has shown the existence of an alternatively spliced Bmi-1 RNA and protein in multiple myeloma cells. The purpose of this research project is to understand the effect of an alternate splice form of Bmi-1 protein on cell cycle and apoptosis in multiple myeloma cells. To understand the effect of this alternate Bmi-1 protein, I first compared the growth rate of different myeloma cell lines and correlated that with the expression of the wild-type Bmi-1 and the alternatively spliced Bmi-1 form. I performed time course experiments and counted the cell numbers in each cell line at various time points. My results show that the myeloma cell lines, which highly express the alternate form of Bmi-1, grew faster than the myeloma cell lines, which mostly express the wild-type form of Bmi-1. Currently I am performing RT-PCR and western blot analysis to confirm the existence of the alternatively spliced Bmi-1 protein. I plan to isolate and sequence the alternatively spliced form of Bmi-1. I also plan to determine the effect of knocking-down Bmi-1 expression on cell cycle and apoptosis by incorporating inducible shRNA viral constructs targeted against Bmi-1 RNA in myeloma cells.
Expression of an alternate form of Bmi-1 in multiple myeloma

Adam Austin, Kristine Veys, Debbie Wong, James Tung
Division of Laboratory Medicine, Nevada Cancer Institute, Las Vegas, NV

Abstract

Tumor stem cells are believed to exist among a heterogeneous group of cells that constitute a tumor. Stem cell or stem cell maintenance genes such as SALL4 and Bmi-1 are often increased in these cancer cells and contribute to cell divisions and cancer cell survival. In particular, high expression of Bmi-1, a member of the polycomb family of transcription factors, is often associated with poor prognosis in cancers. Our laboratory has shown the existence of an alternatively spliced Bmi-1 RNA and protein in multiple myeloma cells. The purpose of this research project is to understand the effect of an alternate splice form of Bmi-1 protein on cell cycle and apoptosis in multiple myeloma cells. We show here that an alternate splice form of Bmi-1 is found in a myeloma cell line, RPMI. The alternate-spliced form can also be observed on the protein level in western blot analysis. We have purified and sequenced the alternate-spliced Bmi-1 RT-PCR product and determined alternate splicing regions. Furthermore, we show that the RPMI (myeloma) and NCI-H9 (AML) cell lines have higher growth rate compared to other myeloma cell lines. Since both RPMI and NCI-H9 both express premnantly the alternate-spliced Bmi-1 form, the growth rate results suggest that the expression of the alternate form may confer growth advantage in cancer cells.

Background

Bmi-1 (B lymphoma mouse Moloney Leukemia virus insertion region) is one of the genes regulated by SALL4 and is a member of the polycomb family of transcription factors. The over-expression of Bmi-1 can be found in a variety of cancers such as breast cancer, glioma, nasopharyngeal cancer, and mantle cell lymphoma.

While Bmi-1 is shown to be involved in the pathogenesis of several cancers, very little is known whether Bmi-1 plays a role in the pathogenesis and progression of multiple myeloma (MM), a cancer of plasma cells characterized by elevated monoclonal antibodies and bone destruction. The pathogenesis of multiple myeloma requires both dysregulation of apoptosis and cell cycle.

We hypothesize that Bmi-1 is expressed and acts as a key regulator of cell growth and apoptosis in multiple myeloma cell lines. Our preliminary data supported this hypothesis. Using flow cytometry and western blot analysis, we demonstrated that Bmi-1 is detected in five myeloma and one myeloid leukemia cell lines.

While Bmi-1 expression is found in these cell lines, our laboratory also found that RPMI and NCI-H9 cell lines expressed an alternate form of Bmi-1 protein. This alternate form is smaller in size and predominates in these two cell lines. Based on these results, we hypothesize that while Bmi-1 expression may increase cell division, the expression of this alternate Bmi-1 form produces a dominant negative effect and further reduces the myeloma cells into cell cycle division and apoptosis.

Objectives

1. Confirm, isolate and sequence the alternate Bmi-1 protein in myeloma cells.
2. Determine whether the alternate Bmi-1 protein correlates with increased cell division.

Results

Presence of an alternate form of Bmi-1

- Figure 1: Bmi-1 is expressed in several multiple myeloma cell lines. Bmi-1 expression in multiple myeloma cells is detected by flow cytometry. Bmi-1 staining is shown in red. Background staining from PE-conjugated secondary antibody is shown in blue.

- Figure 2: DNA analysis of five different myeloma cell lines and an acute myeloid leukemia cell line (NHL) using RT-PCR (reverse transcription-polymerase chain reaction). An alternate form of Bmi-1 is expressed in both RPMI and NCI-H9 cells. The alternate form of Bmi-1 is roughly 600bp shorter than the wild-type.

- Figure 3: Western blot analysis also shows the expression of an alternate form of the Bmi-1 protein. Both RPMI (lane 2) and NCI-H9 (lane 4) express predominantly the alternate splice form of Bmi-1 (lower band).

Nucleotide sequence of alternative form Bmi-1

- Figure 4: Nucleotide sequence of the alternative form of Bmi-1. To get the sequence, the desired band was cut out of the gel and purified. It was then amplified using the same PCR primers that were used initially, and the final product was sequenced.

- Figure 5: Determination of alternate spliced Bmi-1 region. The splice junction (574-4107) was determined using nucleotide BLAST to publish Bmi-1 sequence.

Growth rate for multiple myeloma cell lines

- Figure 6: RPMI and NCI-H9 have higher growth rates. Time course experiments were performed to compare the growth rate of different cell lines. From in vitro analysis of the expression of wild-type Bmi-1 and the alternate Bmi-1 form could be made. The cell lines which highly express the alternate Bmi-1 form (RPMI, NCI-H9) grew much faster than those cell lines which express the wild-type Bmi-1 (Xg3, APRI).

Future Plans

Determine the effect of knocking-down Bmi-1 expression on cell cycle and apoptosis by incorporating inducible shRNA viral constructs targeted against either Bmi-1 wild type and/or variant mRNA in myeloma cells. Then:

1. Determine the effect of altering Bmi-1 expression on cell cycle.
2. Determine the effect of altering Bmi-1 expression on apoptosis.

Literature Cited
